miR-454 is down-regulated in osteosarcomas and suppresses cell proliferation and invasion by directly targeting c-Met

Cell Proliferation

Volumn 48, Issue 3, 2015, Pages 348-355

  Niu, Guangfeng ^a   Li, Bin ^a   Sun, Jianmin ^a   Sun, Li ^a  

^a SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; MICRORNA 454; SCATTER FACTOR RECEPTOR; UNCLASSIFIED DRUG; LUCIFERASE; MIRN454 MICRORNA, HUMAN;

3' UNTRANSLATED REGION; ARTICLE; CANCER GROWTH; CANCER TISSUE; CELL INVASION; CELL PROLIFERATION; CHILD; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; GENE TARGETING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; LUCIFERASE ASSAY; OSTEOSARCOMA; OSTEOSARCOMA CELL LINE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR INVASION; WESTERN BLOTTING; ADULT; BINDING SITE; BONE TUMOR; CELL MOTION; CHEMISTRY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; PLASMID; REPORTER GENE; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ADULT; BINDING SITES; BONE NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CHILD; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, REPORTER; HUMANS; LUCIFERASES; MICRORNAS; OSTEOSARCOMA; PLASMIDS; PROTO-ONCOGENE PROTEINS C-MET; SIGNAL TRANSDUCTION; TRANSFECTION;

EID: 84928823459     PISSN: 09607722     EISSN: 13652184     Source Type: Journal    
DOI: 10.1111/cpr.12187     Document Type: Article

References (40)

1. Hu K, Liao D, Wu W, Han AJ, Shi HJ, Wang F et al. (2014) Targeting the anaphase-promoting complex/cyclosome (APC/C)- bromodomain containing 7 (BRD7) pathway for human osteosarcoma. Oncotarget 5, 3088-3100.
2. Bonuccelli G, Avnet S, Grisendi G, Salerno M, Granchi D, Dominici M et al. (2014) Role of mesenchymal stem cells in osteosarcoma and metabolic reprogramming of tumor cells. Oncotarget 5, 7575-7588.
3. Tang J, Shen L, Yang Q, Zhang C (2014) Overexpression of metadherin mediates metastasis of osteosarcoma by regulating epithelial-mesenchymal transition. Cell Prolif. 47, 427-434.
4. Montanaro L, Mazzini G, Barbieri S, Vici M, Nardi-Pantoli A, Govoni M et al. (2007) Different effects of ribosome biogenesis inhibition on cell proliferation in retinoblastoma protein- and p53-deficient and proficient human osteosarcoma cell lines. Cell Prolif. 40, 532-549.
5. Zhao G, Cai C, Yang T, Qiu X, Liao B, Li W et al. (2013) MicroRNA-221 induces cell survival and cisplatin resistance through PI3K/Akt pathway in human osteosarcoma. PLoS ONE 8, e53906.
6. Ye Z, Jingzhong L, Yangbo L, Lei C, Jiandong Y (2014) Propofol inhibits proliferation and invasion of osteosarcoma cells by regulation of microRNA-143 expression. Oncol. Res. 21, 201-207.
7. Han G, Wang Y, Bi W (2012) C-Myc overexpression promotes osteosarcoma cell invasion via activation of MEK-ERK pathway. Oncol. Res. 20, 149-156.
8. Fei B, Wu H (2012) MiR-378 inhibits progression of human gastric cancer MGC-803 cells by targeting MAPK1 in vitro. Oncol. Res. 20, 557-564.
9. Liao C, Chen W, Fan X, Jiang X, Qiu L, Chen C et al. (2014) MicroRNA-200c inhibits apoptosis in pituitary adenoma cells by targeting the PTEN/Akt signaling pathway. Oncol. Res. 21, 129-136.
10. Bier A, Giladi N, Kronfeld N, Lee HK, Cazacu S, Finniss S et al. (2013) MicroRNA-137 is downregulated in glioblastoma and inhibits the stemness of glioma stem cells by targeting RTVP-1. Oncotarget 4, 665-676.
11. Zhou R, Gong AY, Chen D, Miller RE, Eischeid AN, Chen XM. (2013) Histone deacetylases and NF-kB signaling coordinate expression of CX3CL1 in epithelial cells in response to microbial challenge by suppressing miR-424 and miR-503. PLoS ONE 8, e65153.
12. Yang WB, Chen PH, Hsu Ts FuTF, Su WC, Liaw H et al. (2014) Sp1-mediated microRNA-182 expression regulates lung cancer progression. Oncotarget 5, 740-753.
13. Perilli L, Vicentini C, Agostini M, Pizzini S, Pizzi M, D'Angelo E et al. (2014) Circulating miR-182 is a biomarker of colorectal adenocarcinoma progression. Oncotarget 5, 6611-6619.
14. Karolina DS, Armugam A, Tavintharan S, Wong MT, Lim SC, Sum CF et al. (2011) MicroRNA 144 impairs insulin signaling by inhibiting the expression of insulin receptor substrate 1 in type 2 diabetes mellitus. PLoS ONE 6, e22839.
15. Zhang S, Liu L, Wang R, Tuo H, Guo Y, Yi L et al. (2013) MicroRNA-217 promotes angiogenesis of human cytomegalovirus-infected endothelial cells through downregulation of SIRT1 and FOXO3A. PLoS ONE 8, e83620.
16. Huang J, Zhang SY, Gao YM, Liu YF, Liu YB, Zhao ZG et al. (2014) MicroRNAs as oncogenes or tumour suppressors in oesophageal cancer: potential biomarkers and therapeutic targets. Cell Prolif. 47, 277-286.
17. Ohdaira H, Sekiguchi M, Miyata K, Yoshida K (2012) MicroRNA-494 suppresses cell proliferation and induces senescence in A549 lung cancer cells. Cell Prolif. 45, 32-38.
18. Zhu ED, Li N, Li BS, Li W, Zhang WJ, Mao XH et al. (2014) miR-30b, down-regulated in gastric cancer, promotes apoptosis and suppresses tumor growth by targeting plasminogen activator inhibitor-1. PLoS ONE 9, e106049.
19. Zhao J, Kelnar K, Bader AG (2014) In-depth analysis shows synergy between erlotinib and miR-34a. PLoS ONE 9, e89105.
20. Diao CY, Guo HB, Ouyang YR, Zhang HC, Liu LH, Bu J et al. (2014) Screening for metastatic osteosarcoma biomarkers with a DNA microarray. Asian Pac. J. Cancer Prev. 15, 1817-1822.
21. Yan K, Gao J, Yang T, Ma Q, Qiu X, Fan Q et al. (2012) MicroRNA-34a inhibits the proliferation and metastasis of osteosarcoma cells both in vitro and in vivo. PLoS ONE 7, e33778.
22. Namlos HM, Meza-Zepeda LA, Baroy T, Ostensen IH, Kresse SH, Kuijjer ML et al. (2012) Modulation of the osteosarcoma expression phenotype by microRNAs. PLoS ONE 7, e48086.
23. Liang W, Gao B, Fu P, Xu S, Qian Y et al. (2013) The miRNAs in the pathogenesis of osteosarcoma. Front. Biosci. (Landmark Ed) 18, 788-794.
24. Jones KB, Salah Z, Del Mare S, Galasso M, Gaudio E, Nuovo GJ et al. (2012) miRNA signatures associate with pathogenesis and progression of osteosarcoma. Cancer Res. 72, 1865-1877.
25. Ji F, Zhang H, Wang Y, Li M, Xu W, Kang Y et al. (2013) MicroRNA-133a, downregulated in osteosarcoma, suppresses proliferation and promotes apoptosis by targeting Bcl-xL and Mcl-1. Bone 56, 220-226.
26. Huang G, Nishimoto K, Zhou Z, Hughes D, Kleinerman ES (2012) miR-20a encoded by the miR-17-92 cluster increases the metastatic potential of osteosarcoma cells by regulating Fas expression. Cancer Res. 72, 908-916.
27. Liu L, Nie J, Chen L, Dong G, Du X, Wu X et al. (2013) The oncogenic role of microRNA-130a/301a/454 in human colorectal cancer via targeting Smad4 expression. PLoS ONE 8, e55532.
28. Zhu D, He X, Duan Y, Chen J, Wang J, Sun X et al. (2014) Expression of microRNA-454 in TGF-beta1-stimulated hepatic stellate cells and in mouse livers infected with Schistosoma japonicum. Parasit. Vectors 7, 148.
29. Perfetti A, Greco S, Bugiardini E, Cardani R, Gaia P, Gaetano C et al. (2014) Plasma microRNAs as biomarkers for myotonic dystrophy type 1. Neuromuscul. Disord. 24, 509-515.
30. Fieten H, Spee B, Ijzer J, Kik MJ, Penning LC, Kirpensteijn J. (2009) Expression of hepatocyte growth factor and the proto-oncogenic receptor c-Met in canine osteosarcoma. Vet. Pathol. 46, 869-877.
31. Chattopadhyay C, Grimm EA, Woodman SE (2014) Simultaneous inhibition of the HGF/MET and Erk1/2 pathways affect uveal melanoma cell growth and migration. PLoS ONE 9, e83957.
32. Ha SY, Lee J, Kang SY, Do IG, Ahn S, Park JO et al. (2013) MET overexpression assessed by new interpretation method predicts gene amplification and poor survival in advanced gastric carcinomas. Mod. Pathol. 26, 1632-1641.
33. Akl MR, Ayoub NM, Mohyeldin MM, Busnena BA, Foudah AI, Liu YY et al. (2014) Olive phenolics as c-Met inhibitors: (-)-Oleocanthal attenuates cell proliferation, invasiveness, and tumor growth in breast cancer models. PLoS ONE 9, e97622.
34. Li Y, Wang J, Gao X, Han W, Zheng Y, Xu H et al. (2014) c-Met targeting enhances the effect of irradiation and chemical agents against malignant colon cells harboring a KRAS mutation. PLoS ONE 9, e113186.
35. Entz-Werle N, Lavaux T, Metzger N, Stoetzel C, Lasthaus C, Marec P et al. (2007) Involvement of MET/TWIST/APC combination or the potential role of ossification factors in pediatric high-grade osteosarcoma oncogenesis. Neoplasia 9, 678-688.
36. Wang K, Zhuang Y, Liu C, Li Y (2012) Inhibition of c-Met activation sensitizes osteosarcoma cells to cisplatin via suppression of the PI3K-Akt signaling. Arch. Biochem. Biophys. 526, 38-43.
37. Ferracini R, Angelini P, Cagliero E, Linari A, Martano M, Wunder J et al. (2000) MET oncogene aberrant expression in canine osteosarcoma. J. Orthop. Res. 18, 253-256.
38. Oda Y, Naka T, Takeshita M, Iwamoto Y, Tsuneyoshi M (2000) Comparison of histological changes and changes in nm23 and c-MET expression between primary and metastatic sites in osteosarcoma: a clinicopathologic and immunohistochemical study. Hum. Pathol. 31, 709-716.
39. MacEwen EG, Kutzke J, Carew J, Pastor J, Schmidt JA, Tsan R et al. (2003) c-Met tyrosine kinase receptor expression and function in human and canine osteosarcoma cells. Clin. Exp. Metastasis 20, 421-430.
40. De Maria R, Miretti S, Iussich S, Olivero M, Morello E, Bertotti A et al. (2009) met oncogene activation qualifies spontaneous canine osteosarcoma as a suitable pre-clinical model of human osteosarcoma. J. Pathol. 218, 399-408.